Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO
THE SO WHAT
A $192M upsized IPO for a late-stage sleep apnea drug developer shows public markets will still fund focused, single-asset biotechs with clear endpoints. If you’re building in therapeutics, the bar is less about hype and more about late-stage data and a clean regulatory path.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureBlossom Capital is dipping into defence. Here’s what the VC is looking for
Generalist European capital moving into defence means dual-use AI, sensing, and autonomy startups now have a clearer funding path—and a higher bar on export controls and procurement literacy. If you’re building in this space, tighten your story around NATO-aligned use cases and certification timelines, not just tech novelty.
Startups & Venture222 spinouts, €4.9bn raised: Europe’s top universities for spinout funding in H1 2026
€4.9B across 222 spinouts in six months means European universities are now real origination engines for deep tech and AI infrastructure, not just IP licensing shops. Operators should treat top campuses as strategic BD channels—source tech early, offer industry pilots, and lock in exclusivity where it matters.
Meet the Gen Z AI whiz at the center of a hedge fund meltdown
The meltdown around an AI-focused hedge fund is a reminder that technical brilliance and macro conviction don’t substitute for risk management. If you’re allocating capital to AI-themed funds, diligence the governance and exposure controls as hard as the thesis.
Startups & VentureInvestors love AI, as long as you’re a cloud host
The market is rewarding hyperscalers pouring capex into AI data centers while repricing many downstream AI apps as features, not franchises. If you’re not a cloud host, your pitch needs to be about owning a defensible workflow or data advantage—not just “we use LLMs.”